Latest Breaking News On - Zai lab forward - Page 5 : comparemela.com

Zai Lab and argenx Report Positive Topline Data from ADHERE

Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG.

United kingdomHong kongUnited statesChristine chiouAlina zhangHarald reinhartDemyelinating polyneuropathyShaun maccoun xiaoyu chenDepartment of neurologyExchange commissionZai labHead of global developmentZai lab forwardZai lab limitedHuashan hospital affiliated to fudan universityGroup of huashan rare disease center

MIL-OSI: Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

MIL-OSI: Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomRafaelg amadoAlina zhangRui hua xuChristine chiouGastroenterol hepatolShaun maccoun xiaoyu chenZai labZai lab limitedHead of global oncology researchDrug administrationChina centerZai lab forwardExchange commission

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 Zai Lab Limited today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3.

United statesHong kongUnited kingdomGastroenterol hepatolRui hua xuChristine chiouAlina zhangShaun maccoun xiaoyu chenRafaelg amadoDrug administrationZai lab forwardZai labZai lab limitedHead of global oncology researchChina centerExchange commission

Zai Lab Announces Acceptance by China s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

SHANGHAI, China and CAMBRIDGE, Mass., July 10, 2023 Zai Lab Limited today announced that China’s National Medical Products Administration has accepted the Biologics License Application .

United statesUnited kingdomHong kongChristine chiou lina zhangHarald reinhartShaun maccoun xiaoyu chenZai labZai lab limitedZai lab forwardExchange commissionDrug administrationHead of global developmentChina national medical products administrationLab limitedNational medical products administrationBiologics license application

Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer

Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomShaun maccoun xiaoyu chenChristine chiou lina zhangBilly choJosh smileyZai lab forwardColumbia universityZai lab limitedExchange commissionZai lab deputyYork universityZai lab announces promotion of yajing chenCompany senior viceZai labLab announces promotion